Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial - Huber, RM; Hansen, KH; Paz-Ares Rodríguez, L (J Thorac Oncol, 2020)
et al.